Opera Trading Capital’s Halozyme HALO Stock Holding History

Opera Trading Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-14,990	Closed	-$272K	–	119
2018 Q3	$272K	Buy	+14,990	New	+$263K	0.05%	107

Other funds holding HALO

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Opera Trading Capital's HALO Position: Q4 2018 in Review

Opera Trading Capital sold out of Halozyme (HALO) in Q4 2018, closing a stake of 14,990 shares — an estimated $272K sold.

Opera Trading Capital first reported a position in HALO in Q3 2018 and held it in 1 quarter. The position peaked at $272K in Q3 2018. 195 funds tracked by Wall St. Rank hold HALO as of Q4 2018.

Opera Trading Capital reported no remaining Halozyme position as of Q4 2018 after selling out during the quarter.
Opera Trading Capital sold 14,990 Halozyme shares in Q4 2018, an estimated $272K.
Opera Trading Capital first reported a position in Halozyme in Q3 2018 and held it in 1 quarter.
Opera Trading Capital's Halozyme position peaked at $272K in Q3 2018.
195 funds tracked by Wall St. Rank held Halozyme as of Q4 2018.

Based on Opera Trading Capital's 13F filing for Q4 2018, filed 22 Jan 2019.